These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 27544058)

  • 21. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
    Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
    Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
    Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
    Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer.
    Hammoud ZT; Kesler KA; Ferguson MK; Battafarrano RJ; Bhogaraju A; Hanna N; Govindan R; Mauer AA; Yu M; Einhorn LH
    Dis Esophagus; 2006; 19(2):69-72. PubMed ID: 16643172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.
    Depypere L; Moons J; Lerut T; De Hertogh G; Peters C; Sagaert X; Coosemans W; Van Veer H; Nafteux P
    Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival.
    Lutfi W; Martinez-Meehan D; Dhupar R; Christie N; Sarkaria I; Ekeke C; Baker N; Luketich JD; Okusanya OT
    J Surg Oncol; 2020 Mar; 121(4):654-661. PubMed ID: 31970776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
    Ruffier-Loubière A; Janoray G; Chapet S; de Calan L; Dumont P; Dorval É; Orain I; Calais G
    Cancer Radiother; 2015 Aug; 19(5):322-30. PubMed ID: 26215366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh.
    Defoe SG; Pennathur A; Flickinger JC; Heron DE; Gibson MK; Luketich JD; Greenberger JS
    Am J Clin Oncol; 2011 Dec; 34(6):587-92. PubMed ID: 22101387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution.
    Malaisrie SC; Untch B; Aranha GV; Mohideen N; Hantel A; Pickleman J
    Arch Surg; 2004 May; 139(5):532-8; discussion 538-9. PubMed ID: 15136354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.
    Shao MS; Wong AT; Schwartz D; Weiner JP; Schreiber D
    Ann Thorac Surg; 2016 Jun; 101(6):2148-54. PubMed ID: 27016842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drivers of 30- and 90-day Postoperative Death After Neoadjuvant Chemoradiation for Esophageal Cancer.
    Horne ZD; Wegner RE; Colonias A; Weksler B; Glaser SM; Kalash R; Beriwal S
    Ann Thorac Surg; 2020 Mar; 109(3):921-926. PubMed ID: 31846643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
    Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
    J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer.
    Haisley KR; Laird AE; Nabavizadeh N; Gatter KM; Holland JM; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    JAMA Surg; 2016 Nov; 151(11):e162743. PubMed ID: 27627765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
    Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
    Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction chemoradiation therapy prior to esophagectomy is associated with superior long-term survival for esophageal cancer.
    Speicher PJ; Wang X; Englum BR; Ganapathi AM; Yerokun B; Hartwig MG; D'Amico TA; Berry MF
    Dis Esophagus; 2015; 28(8):788-96. PubMed ID: 25212528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer?
    Lee A; Wong AT; Schwartz D; Weiner JP; Osborn VW; Schreiber D
    Ann Thorac Surg; 2016 Aug; 102(2):433-8. PubMed ID: 27154156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.